Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Саратовский государственный медицинский университет им. В.И.Разумовского Минздрава России
Список исп. литературыСкрыть список 1. Autism and Developmental Disabilities Monitoring Network. Prevalence of the Autism Spectrum Disorders (ASDs) in Multiple Areas of the United States, 2004 and 2006. Atlanta, GA. Centers for Disease Control and Prevention 2009; http://www.cdc.gov/ncbddd/ autism/states/ADDMCommunityReport2009 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC. American Psychiatric Association 2000. 3. Zwaigenbaum L, Bryson S, Lord C et al. Clinical assessment and management of toddlers with suspected autism spectrum disorder: insights from studies of high-risk infants. Pediatrics 2009; 123 (5): 1383–91. 4. Myers SM, Johnson CP. American Academy of Pediatrics, Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007; 120 (5): 1162–82. 5. Myers SM. Management of autism spectrum disorders in primary care. Pediatr Ann 2009; 38 (1): 42–9. 6. National Autism Center. National Standards Report. Randolph, MA. National Autism Center 2009; http://www.nationalautismcenter 7. National Research Council, Committee on Educational Interventions for Children With Autism. Educating Children With Autism. Washington, DC. National Academies Press 2001; http://books.nap.edu/ catalog.php?record_id_10017 8. Warren Z, Veenstra-Vander Weele J, Stone W et al. Therapies for Children With Autism Spectrum Disorders. Comparative Effectiveness Review 26. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract 290-02-HHSA-290-2007-10065-I.) AHRQ Publication 11-EHC035-EF. Rockville, MD. Agency for Healthcare Research and Quality 2007; www.http://effectivehealthcare.ahrq.gov/reports/final.cfm 9. Krishnaswami S, McPheeters ML, Veenstra-Vander Weele J. A systematic review of secretin for children with autism spectrum disorders. Pediatrics 2011; 127 (5); http://www.pediatrics.org/cgi/content/ full/127/5/eXXX 10. Lord C, Risi S, Lambrecht L et al. The Autism Diagnostic Observation Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Dis 2000; 30 (3): 205–23. 11. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Dis 1994; 24 (5): 659–85. 12. Owens DK, Lohr KN, Atkins D et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions. Agency for Healthcare Research and Quality and the effective healthcare program. J Clin Epid 2010; 63 (5): 513–23. 13. Aman MG, Hollway JA, McDougle CJ et al. Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 2008; 18 (3): 227–36. 14. Aman MG, Arnold LE, McDougle CJ et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adol Psychopharmacol 2005; 15 (6): 869–84. 15. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiat 2005; 162 (7): 1361–9. 16. McDougle CJ, Scahill L, Aman MG et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiat 2005; 162 (6): 1142–8. 17. Martin A, Scahill L, Anderson GM et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiat 2004; 161 (6): 1125–7. 18. McCracken JT, McGough J, Shah B et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347 (5): 314–21. 19. Arnold LE, Vitiello B, McDougle C et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adol Psychiat 2003; 42 (12): 1443–50. 20. Williams SK, Scahill L, Vitiello B et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adol Psychiat 2006; 45 (4): 431–9. 21. Anderson GM, Scahill L, McCracken JT et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiat 2007; 61 (4): 545–50. 22. Pandina GJ, Bossie CA, Youssef E et al. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Dis 2007; 37 (2): 367–73. 23. Shea S, Turgay A, Carroll A et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114 (5); http://www.pediatrics.org/cgi/content/full/114/5/e634 24. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21 (6): 450–5. 25. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiat 2003; 64 (9): 1039–47. 26. Marcus RN, Owen R, Kamen L et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adol Psychiat 2009; 48 (11): 1110–9. 27. Owen R, Sikich L, Marcus RN et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124 (6): 1533–40. 28. Akhondzadeh S, Erfani S, Mohammadi MR et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther 2004; 29 (2): 145–50. 29. Correia CT, Almeida JP, Santos PE et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenom J 2010; 10 (5): 418–30. 30. Hollander E, Phillips A, Chaplin W et al. A placebo-controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacol 2005; 30 (3): 582–9. 31. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002; 44 (10): 652–9. 32. King BH, Hollander E, Sikich L et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiat 2009; 66 (6): 583–90. 33. Owley T, Brune CW, Salt J et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res 2010; 3 (1): 1–7. 34. Henry CA, Steingard R, Venter J et al. Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. J Child Adolesc Psychopharmacol 2006; 16 (1–2): 187–95. 35. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiat 2005; 62 (11): 1266–74. 36. Posey DJ, Aman MG, McCracken JT et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiat 2007; 61 (4): 538–44. 37. Jahromi LB, Kasari CL, McCracken JT et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Dis 2009; 39 (3): 395–404. 38. Nickels K, Katusic SK, Colligan RC et al. Stimulant medication treatment of target behaviors in children with autism: a population based study. J Dev Behav Pediatr 2008; 29 (2): 75–81. 39. Posey DJ, Puntney JI, Sasher TM et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adol Psychopharmacol 2004; 14 (2): 233–41. 40. Stigler KA, Desmond LA, Posey DJ et al. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adol Psychopharmacol 2004; 14 (1): 49–56. 41. Scahill L, McDougle CJ, Williams SK et al. Children’s Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adol Psychiat 2006; 45 (9): 1114–23. 42. Anderson LT, Campbell M, Adams P et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Dis 1989; 19 (2): 227–39. 43. Anderson LT, Campbell M, Grega DM et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiat 1984; 141 (10): 1195–202. 44. Aman MG, Lam KS, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adol Psychopharmacol 2005; 15 (1): 116–26. 45. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Dis 2003; 33 (5): 527–34. 46. Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Dis 2009; 39 (9): 1339–49. 47. Amminger GP, Berger GE, Schafer MR et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiat 2007; 61 (4): 551–3. 48. Arnold LE, Aman MG, Cook AM et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adol Psychiat 2006; 45 (10): 1196–205. 49. Rossignol DA, Rossignol LW, Smith S et al. Hyperbaric treatment for children with autism: a multicenter, randomized, doubleblind, controlled trial. BMC Pediatr 2009; 9: 21. 50. Guastella AJ, Einfeld SL, Gray KM et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiat 2010; 67 (7): 692–4. 51. Erickson CA, Posey DJ, Stigler KA et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacol (Berl) 2007; 191 (1): 141–7. 52. Walkup JT, Albano AM, Piacentini J et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359 (26): 2753–66. 53. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292 (16): 1969–76. 54. March J, Silva S, Petrycki S et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292 (7): 807–20.